Skip to content
RNACCartesian Therapeutics, Inc.

Earnings

When Cartesian Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

47 quarters. Mar 31, 2015 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 8, before the open

Mon, Mar 8, 2027in 110 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 5 – 16

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$2.40M
Revenue, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 −100.0%, Q4 2025 n/m
Net income
-$92.58M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 −0.7%, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 −8.0%, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$0.00No Q3 2025 on file

Latest results

  1. Q3 2026Nov 5, 2026, before the openThe release0.7%by the close of Nov 5
    Revenue
    $0.00
    —
    Net income
    -$11.47M
    N/M
    EPS
    -$0.38
    N/M
  2. Q2 2026Aug 6, 2026, before the openThe release+4.9%by the close of Aug 6
    Revenue
    $0.00
    —
    Net income
    $15.77M
    −0.7%
    EPS
    $0.46
    −8.0%
  3. Q1 2026Apr 30, 2026, before the openThe release3.9%by the close of Apr 30
    Revenue
    $0.00
    −100.0%
    Net income
    -$39.18M
    N/M
    EPS
    -$1.46
    N/M
  4. Q4 2025Mar 9, 2026, before the openThe release+31.1%by the close of Mar 9
    Revenue
    $2.40M
    —
    Net income
    -$92.58M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 5, 2026 · pre-marketNov 5, 202636 d10-Q$0.00—-$0.380.7%
Q2 2026Jun 30, 2026Aug 6, 2026 · pre-marketAug 6, 202637 d10-Q$0.00—$0.46+4.9%
Q1 2026Mar 31, 2026Apr 30, 2026 · pre-marketApr 30, 202630 d10-Q$0.00−100.0%-$1.463.9%
FY 2025
Q4 2025derivedDec 31, 2025Mar 9, 2026 · pre-marketMar 9, 202668 d10-K$2.40M——+31.1%
Q3 2025Sep 30, 2025Nov 6, 2025 · pre-marketNov 6, 202537 d10-Q$0.00—-$1.381.2%
Q2 2025Jun 30, 2025Aug 7, 2025 · pre-marketAug 7, 202538 d10-Q$0.00−100.0%$0.507.5%
Q1 2025Mar 31, 2025May 8, 2025 · pre-marketMay 8, 202538 d10-Q$400.00K−93.2%-$0.68+5.5%
FY 2024
Q4 2024derivedDec 31, 2024Mar 13, 2025 · pre-marketMar 13, 202572 d10-K———5.0%
Q3 2024Sep 30, 2024Nov 7, 2024 · pre-marketNov 7, 202438 d10-Q$0.00−100.0%-$1.13+0.7%
Q2 2024Jun 30, 2024Aug 8, 2024 · pre-marketAug 8, 202439 d10-Q$33.27M+533.9%$0.549.4%
Q1 2024Mar 31, 2024May 8, 2024 · pre-marketMay 8, 202438 d10-Q$5.84M−1.7%-$10.50—
Earlier years, FY 2015 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 5, 2026000111
10-QAug 6, 2026000101
10-QApr 30, 2026000082
10-KMar 9, 2026000064
10-QNov 6, 2025000120
10-QAug 7, 2025000099
10-QMay 8, 2025000085
10-KMar 13, 2025000060
10-QNov 7, 2024000124
10-QAug 8, 2024000102

Provenance

ProvenanceData status and checks

Cartesian Therapeutics, Inc. · CIK 1453687 · Engraved from SEC EDGAR